BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 26718131)

  • 1. Targeted therapy for gastric cancer: Current status and future directions (Review).
    Yuan DD; Zhu ZX; Zhang X; Liu J
    Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in gastric cancer.
    Thiel A; Ristimäki A
    APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric Carcinoma at the Era of Targeted Therapies.
    Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
    Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced HER2-positive gastric cancer: current and future targeted therapies.
    Pazo Cid RA; Antón A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?
    Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
    Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
    Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
    Wong H; Yau T
    Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
    Singh R; Kim WJ; Kim PH; Hong HJ
    Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.
    Luis M; Tavares A; Carvalho LS; Lara-Santos L; Araújo A; de Mello RA
    World J Gastroenterol; 2013 Oct; 19(38):6383-97. PubMed ID: 24151357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
    Javle M; Smyth EC; Chau I
    Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Can Gastric Cancer Molecular Profiling Guide Future Therapies?
    Corso S; Giordano S
    Trends Mol Med; 2016 Jul; 22(7):534-544. PubMed ID: 27260398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy for gastric cancer.
    Smyth EC; Cunningham D
    Curr Treat Options Oncol; 2012 Sep; 13(3):377-89. PubMed ID: 22552927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in targeted therapy for gastric cancer based on tumor driver genes.
    Wu S; Xu P; Zhang F
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy.
    Lee J; Bass AJ; Ajani JA
    Am Soc Clin Oncol Educ Book; 2016; 35():104-11. PubMed ID: 27249691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
    Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
    Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
    Bilici A
    World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel pharmaceutical treatment approaches for gastric cancer].
    Lordick F
    Pathologe; 2017 Mar; 38(2):87-92. PubMed ID: 28220199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress in targeted therapies for gastric cancer.
    Ye M; Xiu LJ; Ji QQ; Zhang YC; Sun YW; Zhao Y; Wang D; Li YJ; Wang XW; Yue XQ; Sun DZ
    Int J Clin Pharmacol Ther; 2022 Dec; 60(12):509-514. PubMed ID: 36197788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.